President Obama Pushes BRAIN Initiative Forward
|
By LabMedica International staff writers Posted on 09 Apr 2013 |
In his State of the Union address, US President Obama outlined his strategy for creating jobs and building a growing, flourishing middle class by making an historic investment in medical research and development.
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
Latest BioResearch News
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more
Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
Respiratory viruses such as influenza A/B and SARS‑CoV‑2 continue to burden urgent care and emergency settings, where rapid, reliable differentiation guides therapy and infection control.... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







